Inflammatory biomarkers and bladder cancer prognosis: a systematic review.

[1]  R. Thompson,et al.  Pretreatment neutrophil-to-lymphocyte ratio is associated with advanced pathologic tumor stage and increased cancer-specific mortality among patients with urothelial carcinoma of the bladder undergoing radical cystectomy. , 2014, European urology.

[2]  K. Pummer,et al.  Validation of the pretreatment derived neutrophil–lymphocyte ratio as a prognostic factor in a European cohort of patients with upper tract urothelial carcinoma , 2014, British Journal of Cancer.

[3]  Wenhui Qian,et al.  Prognostic Role of NLR in Urinary Cancers: A Meta-Analysis , 2014, PloS one.

[4]  A. Eggermont,et al.  Cutaneous melanoma , 2014, The Lancet.

[5]  Arcadi Navarro,et al.  Application of Multi-SNP Approaches Bayesian LASSO and AUC-RF to Detect Main Effects of Inflammatory-Gene Variants Associated with Bladder Cancer Risk , 2013, PloS one.

[6]  B. Wullich,et al.  Bladder cancer – the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register clinicaltrials.gov , 2013, BMC Urology.

[7]  A. Hemal,et al.  Preoperative neutrophil/lymphocyte ratio predicts overall survival and extravesical disease in patients undergoing radical cystectomy. , 2013, Journal of endourology.

[8]  B. Têtu,et al.  High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer. , 2013, Human pathology.

[9]  C. Pan,et al.  Prognostic significance of heat shock proteins in urothelial carcinoma of the urinary bladder , 2013, Histopathology.

[10]  Y. Kanai,et al.  Prognostic risk stratification of patients with urothelial carcinoma of the bladder with recurrence after radical cystectomy. , 2013, The Journal of urology.

[11]  S. Urakami,et al.  Impact of C‐reactive protein kinetics on survival of patients with advanced urothelial carcinoma treated by second‐line chemotherapy with gemcitabine, etoposide and cisplatin , 2012, BJU international.

[12]  A. Hartmann,et al.  First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival , 2012, World Journal of Urology.

[13]  F. Marincola,et al.  Cancer classification using the Immunoscore: a worldwide task force , 2012, Journal of Translational Medicine.

[14]  Kwangsung Park,et al.  Utility of inflammation-based prognostic scoring in patients given systemic chemotherapy first-line for advanced inoperable bladder cancer. , 2012, Japanese journal of clinical oncology.

[15]  N. Malats,et al.  Cyclooxygenase-2 Expression in Bladder Cancer and Patient Prognosis: Results from a Large Clinical Cohort and Meta-Analysis , 2012, PloS one.

[16]  Y. Tsai,et al.  Prognostic relevance of preoperative circulating CD8-positive lymphocytes in the urinary bladder recurrence of urothelial carcinoma. , 2012, Urologic oncology.

[17]  M. Yokoyama,et al.  Development of a nomogram incorporating serum C-reactive protein level to predict overall survival of patients with advanced urothelial carcinoma and its evaluation by decision curve analysis , 2012, British Journal of Cancer.

[18]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[19]  Mårten Fernö,et al.  A Molecular Taxonomy for Urothelial Carcinoma , 2012, Clinical Cancer Research.

[20]  Y. Horiguchi,et al.  Prognostic value of neutrophil-to-lymphocyte ratio and establishment of novel preoperative risk stratification model in bladder cancer patients treated with radical cystectomy. , 2012, Urology.

[21]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[22]  Douglas Hanahan,et al.  Accessories to the Crime: Functions of Cells Recruited to the Tumor Microenvironment Prospects and Obstacles for Therapeutic Targeting of Function-enabling Stromal Cell Types , 2022 .

[23]  S. Calderwood,et al.  Heat Shock Proteins: Conditional Mediators of Inflammation in Tumor Immunity , 2012, Front. Immun..

[24]  Jens-Peter Volkmer,et al.  Three differentiation states risk-stratify bladder cancer into distinct subtypes , 2012, Proceedings of the National Academy of Sciences.

[25]  T. Todenhöfer,et al.  Development of a new outcome prediction model in carcinoma invading the bladder based on preoperative serum C‐reactive protein and standard pathological risk factors: the TNR‐C score , 2011, BJU international.

[26]  O. Winqvist,et al.  FOXP3 and survival in urinary bladder cancer , 2011, BJU international.

[27]  Yair Lotan,et al.  Statistical consideration for clinical biomarker research in bladder cancer. , 2010, Urologic oncology.

[28]  Carmine Zoccali,et al.  Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  Carsten Denkert,et al.  Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  Zlatko Trajanoski,et al.  In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  N. Sato,et al.  Human leukocyte antigen class I down‐regulation in muscle‐invasive bladder cancer: Its association with clinical characteristics and survival after cystectomy , 2009, Cancer science.

[32]  L. Lacombe,et al.  Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy. , 2009, European urology.

[33]  R. D. Mittal,et al.  Cytokine gene polymorphisms are associated with risk of urinary bladder cancer and recurrence after BCG immunotherapy , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[34]  K. Aozasa,et al.  Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation. , 2009, The Journal of urology.

[35]  Zhiquan Hu,et al.  Costimulatory molecule B7-H1 on the immune escape of bladder cancer and its clinical significance , 2009, Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban.

[36]  G. Freeman,et al.  Interaction of human PD-L1 and B7-1. , 2008, Molecular immunology.

[37]  S. Boorjian,et al.  T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival , 2008, Clinical Cancer Research.

[38]  R. D. Mittal,et al.  Anti- and proinflammatory cytokine gene polymorphism and genetic predisposition: association with smoking, tumor stage and grade, and bacillus Calmette-Guérin immunotherapy in bladder cancer. , 2008, Cancer genetics and cytogenetics.

[39]  K. Kihara,et al.  C‐reactive protein level predicts prognosis in patients with muscle‐invasive bladder cancer treated with chemoradiotherapy , 2008, BJU international.

[40]  G. Freeman,et al.  Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.

[41]  V. Reuter,et al.  CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma , 2007, Proceedings of the National Academy of Sciences.

[42]  Koichiro Matsumoto,et al.  Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers , 2007, Cancer Immunology, Immunotherapy.

[43]  J. Bartlett,et al.  The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder , 2006, British Journal of Cancer.

[44]  Z. Trajanoski,et al.  Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome , 2006, Science.

[45]  I. Olkin,et al.  The case of the misleading funnel plot , 2006, BMJ : British Medical Journal.

[46]  N. Sato,et al.  Effect of Human Leukocyte Antigen Class I Expression of Tumor Cells on Outcome of Intravesical Instillation of Bacillus Calmette-Guerin Immunotherapy for Bladder Cancer , 2006, Clinical Cancer Research.

[47]  V. Boddi,et al.  Prognostic role of the tumor-associated tissue inflammatory reaction in transitional bladder cell carcinoma. , 2006, Oncology reports.

[48]  Douglas G Altman,et al.  Reporting recommendations for tumor marker prognostic studies. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  N. Malats,et al.  P53 as a prognostic marker for bladder cancer: a meta-analysis and review. , 2005, The Lancet. Oncology.

[50]  R. Millikan,et al.  Polymorphisms in inflammation genes and bladder cancer: from initiation to recurrence, progression, and survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  W. Sauerbrei,et al.  Reporting recommendations for tumor marker prognostic studies (REMARK). , 2005, Journal of the National Cancer Institute.

[52]  H. Samaratunga,et al.  Significance of stromal reaction patterns in invasive urothelial carcinoma. , 2005, American journal of clinical pathology.

[53]  J. Montie.  Prognosis of Muscle-Invasive Bladder Cancer: Difference Between Primary and Progressive Tumours and Implications for Therapy , 2005 .

[54]  J. Féher,et al.  Immunological studies of patients with tumours of the prostate and bladder , 2005, International Urology and Nephrology.

[55]  J. Flamm.  The value of tumor-associated tissue inflammatory reaction in primary superficial bladder cancer , 2004, Urological Research.

[56]  K. Syrigos,et al.  Clinical significance of heat shock protein-70 expression in bladder cancer. , 2003, Urology.

[57]  T. Nomura,et al.  Control of Regulatory T Cell Development by the Transcription Factor Foxp3 , 2002 .

[58]  S. Hamilton-Dutoit,et al.  Intense inflammation in bladder carcinoma is associated with angiogenesis and indicates good prognosis , 2002, British Journal of Cancer.

[59]  Yingdong Zhao,et al.  Prospective molecular profiling of melanoma metastases suggests classifiers of immune responsiveness. , 2002, Cancer research.

[60]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[61]  T. Wheeler,et al.  Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. , 2002, The Journal of urology.

[62]  S. Hamilton-Dutoit,et al.  Intense inflammation in bladder carcinoma indicate good prognosis , 2001 .

[63]  M. Nakagawa,et al.  Prognostic value of tumor‐associated macrophage count in human bladder cancer , 2000, International journal of urology : official journal of the Japanese Urological Association.

[64]  J. Goldstein,et al.  Expression of class I histocompatibility antigens in transitional cell carcinoma of the urinary bladder in relation to survival , 1991, Cancer.

[65]  D. Rosell,et al.  Superficial bladder cancer: survival and prognostic factors. , 1991, European urology.

[66]  J. Flamm,et al.  Factors affecting survival in primary superficial bladder cancer. , 1990, European urology.

[67]  P. Guinan,et al.  Prognostic value of cell surface antigens using immunoperoxidase methods in bladder carcinoma. , 1982, Urology.

[68]  W. Catalona,et al.  Prognostic value of host immunocompetence in urologic cancer patients. , 1975, The Journal of urology.

[69]  G. Freeman,et al.  Programmed Death-1 Ligand 1 Interacts Specifically with the B 7-1 Costimulatory Molecule to Inhibit T Cell Responses , 2022 .